A5065794180- Tuberculosis Research and Epidemiology
- Mycobacterium research and diagnosis
- Viral Infections and Outbreaks Research
- Vaccine Coverage and Hesitancy
- Immune responses and vaccinations
- HIV/AIDS Research and Interventions
- Pneumocystis jirovecii pneumonia detection and treatment
- Antibiotic Resistance in Bacteria
- Pneumonia and Respiratory Infections
- Mental Health and Patient Involvement
- SARS-CoV-2 and COVID-19 Research
- HIV Research and Treatment
- Innovation and Socioeconomic Development
- Health Policy Implementation Science
- Malaria Research and Control
- HIV/AIDS drug development and treatment
- Immunodeficiency and Autoimmune Disorders
- Adolescent Sexual and Reproductive Health
- Computational Drug Discovery Methods
- Global Maternal and Child Health
- Global Public Health Policies and Epidemiology
- Sex work and related issues
- vaccines and immunoinformatics approaches
Unitaid
2021-2024
Médecins Sans Frontières
2024
TB Alliance
2013-2024
World Health Organization
2024
Médecins Sans Frontières
2024
Aeras
2020
Kenya Medical Research Institute
2020
Infectious Diseases Research Collaboration
2020
Johns Hopkins University
2002-2005
Johns Hopkins Medicine
2005
The pathogenesis of tuberculosis involves multiple phases and is believed to involve both a carefully deployed series adaptive bacterial virulence factors inappropriate host immune responses that lead tissue damage. A defined Mycobacterium mutant strain lacking the sigH -encoded transcription factor showed distinctive infection phenotype. In resistant C57BL/6 mice, achieved high counts in lung spleen persisted tissues pattern identical those wild-type bacteria. Despite burden, produced...
Simpler, shorter, safer and more effective treatments for tuberculosis that are easily accessible to all people with desperately needed. In 2016, the World Health Organization (WHO) developed target regimen profiles treatment of make drug developers aware both important features regimens, patient programmatic needs at country level. view recent ground-breaking advances in treatment, WHO has revised updated these profiles. We used a similar process as 2016 profiles, including baseline...
Monoclonal antibodies (mAbs) are revolutionizing management of non-communicable diseases in high-income countries and increasingly being advanced for a range infectious (IDs). However, access to existing mAbs is limited low- middle-income (LMICs), investment developing fit-for-purpose IDs that disproportionately affect LMICs has been limited. Underlying these barriers systemic challenges, including lack commercial incentives target LMIC markets complexity manufacturing regulatory processes....
Long-acting antiretroviral drugs have emerged as exciting treatment and preexposure prophylaxis (PrEP) options for people with HIV at risk of HIV. regimens may improve dosing convenience, tolerability cost compared current daily-based oral therapy. They can also circumvent stigma associated therapy both PrEP, thereby improving adherence outcomes. Yet, multiple challenges remain, many specific to low-income middle-income countries (LMICs), where the epidemic is most concentrated prevention...
The World Health Organization has developed target product profiles containing minimum and optimum targets for key characteristics tests tuberculosis treatment monitoring optimization.Tuberculosis optimization refers to initiating or switching an effective regimen that results in a high likelihood of good outcome.The also cover cure conducted at the end treatment.The development was informed by stakeholder survey, cost-effectiveness analysis patient-care pathway analysis.Additional feedback...
ABSTRACT Mycobacterium microti is phylogenetically closely related to tuberculosis and a member of that complex organisms. It curved, acid-fast bacillus naturally attenuated with narrow host range for Microtus species only. In this study, we confirm the unique susceptibility voles infection M. relative resistance mice significantly lower organism burden after 8 weeks infection. addition, histopathologic examination lungs reveals lack cellular, granulomatous aggregates characteristically seen...
Fluoroquinolone resistance in tuberculosis may rapidly emerge. Mice infected with high titers of aerosolized Mycobacterium and treated for 8 weeks four concentrations moxifloxacin (0.125, 0.25, 0.50, 1.0%) mixed into the diet had drug 2.4, 4.1, 5.3, 17.9 microg/ml, respectively, blood. Selection fluoroquinolone-resistant mutants occurred all surviving mice.
A large proportion of people with latent tuberculosis live in malaria-endemic areas, so co-infection these two organisms is likely to be common. To determine whether there might a biologic interaction between pathogens vivo, we infected mice Mycobacterium and then non-lethal strain Plasmodium yoelii eight weeks later. Mice chronically M. simulate the equilibrium pathogen host thought exist human infection. Co-infected were less able contain growth lung, spleen, liver (mean +/- SEM log10...
Techniques to improve the sensitivity of smear microscopy would facilitate early tuberculosis (TB) diagnosis and disease control, especially in low-income countries where positive predictive value is high. C(18)-carboxypropylbetaine (CB-18) a zwitterionic detergent that helps compensate for innate buoyancy mycobacteria, potentially enhancing recovery by centrifugation. Previous data suggest CB-18 may increase smear, culture, molecular amplification diagnostic testing. The goal present study...
Tuberculosis is the deadliest infection of our time. In contrast, about 11,000 people died Ebola between 2014 and 2016. Despite this manifest difference in mortality, there now a vaccine licensed United States by European Medicines Agency, with up to 100% efficacy against Ebola. The developments that led trialing were historic unprecedented. single TB (BCG) has limited efficacy. There dire need for more efficacious vaccine. To deploy such vaccines, trials are needed sites combine high...
OPINION article Front. Reprod. Health, 24 August 2023Sec. HIV and STIs Volume 5 - 2023 | https://doi.org/10.3389/frph.2023.1238813
Tuberculosis is the deadliest infection of our time, with about 1.3 million deaths in 2017. In contrast, 11,000 people died Ebola between 2014 and 2016. Despite this manifest difference mortality, there now a licensed vaccine up to 100% efficacy against Ebola. The developments that led trialing licensure were historic unprecedented. single TB (BCG) has limited efficacy. There dire need for new, more efficacious vaccine. order license deploy such vaccines, trials are needed number sites...
Abstract Tuberculosis is the deadliest infection of our time. In contrast, about 11,000 people died Ebola between 2014 and 2016. Despite this manifest difference in mortality, there now a vaccine licensed United States by European Medicines Agency, with up to 100% efficacy against Ebola. The developments that led trialing were historic unprecedented. single TB (BCG) has limited efficacy. There dire need for more efficacious vaccine. To deploy such vaccines, trials are needed sites combine...
Abstract Tuberculosis is the deadliest infection of our time. In contrast, about 11,000 people died Ebola between 2014 and 2016. Despite this manifest difference in mortality, there now a vaccine licensed United States by European Medicines Agency, with up to 100% efficacy against Ebola. The developments that led trialing were historic unprecedented. single TB (BCG) has limited efficacy. There dire need for more efficacious vaccine. To deploy such vaccines, trials are needed sites combine...